 5-Fluorouracil and oxaliplatin FOLFOX-Regimen in combination with bevacizumab is regarded as standard first-line treatment in metastatic colorectal cancer Saltz et al., 2008. Current studies established the role of the FOLFOXIRI regimen Souglakos et al., 2006, Falcone et al., 2007. A further intensification of the therapy seems feasible yielding response rates up to 84 and a disease control rate up to 100 Falcone, 2008, Santomaggio, 2009, Masi, 2010. This trial evaluates the activity of an intensified first-line therapy for metastatic colorectal cancer compared to standard treatment. 